Navigation Links
FDA Accepts Sanofi Pasteur's Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
Date:8/26/2010

uld affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2009.  Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.ContactsUS Media RelationsAmy BaTel: 570-957-0717amy.ba@sanofi-aventis.comwww.sanofipasteur.us
'/>"/>
SOURCE Sanofi Pasteur
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
2. FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
3. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
4. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
5. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
6. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
10. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
11. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ) ... December 31, 2014. Total revenues were $4.3 million for ... the three months ended December 31, 2013.  Net loss ... 31, 2014 as compared to a net loss of ... were $19.4 million and net loss was $22.1 million ...
(Date:3/2/2015)... Therapeutics, Inc. (NASDAQ: HALO ) today reported financial results ... 2014. Financial highlights for the fourth quarter include revenues of ... $0.04 per share. This compares to revenues of $12.5 million ... share, for the fourth quarter of 2013. Financial highlights for ... a net loss of $68.4 million, or $0.56 per share. ...
(Date:3/2/2015)... Biomedical, Inc., a leading processor of human tissue, synthetics, ... it hired Lou Barnes as President and ... formed UMTB Biomedical as a wholly-owned subsidiary to acquire ... 2014. UMTB is the oldest tissue bank in the ... veteran of the tissue banking industry, having most recently ...
Breaking Medicine Technology:DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 2Vivex Biomedical, Inc. Announces New Chief Operating Officer of Tissue Bank 3
... Cobalis Corp. (Pink Sheets: CLSC ... provide investors and shareholders with further details and the latest ... issues. Shareholders and investors MUST RSVP to participate ... 2010 at 1:15pm Pacific Time. Interested parties may RSVP to ...
... (Nasdaq: GNBT, www.generex.com ), the leader in drug ... the mouth, today announced that it has been awarded ... Intellectual Property Office granted Canadian Patent No. 2,401,942, a ... This new patent increases the number of ...
Cached Medicine Technology:Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010 2Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System 2Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System 3
(Date:3/2/2015)... Clearwater, FL (PRWEB) March 02, 2015 ... comply with Title VI of the Civil Rights Act, ... (LEP) and hearing loss are bringing light to the ... Bureau statistics reveal that nearly 1 in 20 U.S. ... 1 in 10 in some major cities.(1) Stratus ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Doctors in ... be a better predictor of outcomes for people with ... read details of the new study on the ... at the University of Eastern Piedmont followed the cases ... pleurodesis treatment for excess lung fluid. , “Persistent ...
(Date:3/2/2015)... Gummy smile reduction expert, Dr. ... can involve one or several procedures to reduce the appearance ... for a more even gum line. Dr. Farnoosh is the ... that can permanently lighten discolored or naturally dark gums. ... a personalized treatment plan to address a patient’s specific needs ...
(Date:3/2/2015)... 2015 After a rigorous evaluation process ... pricing and long-term strategy, Blood Centers of America (BCA) ... for member centers’ testing needs. , BCA, which comprises ... than 30 percent of the U.S. blood supply, made ... is committed to drive cost savings to members,” said ...
(Date:3/2/2015)... 2015 New York singer/songwriter Richie ... delivering a plenary address entitled Finding the Music ... of Healing and Recovery at this year’s National ... Executive Summit (BHES).     , With more than 300 ... been recorded by some of the biggest names ...
Breaking Medicine News(10 mins):Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 4Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2
... afflicting as many as 3.4% of all adults. Like other ... to society, often leading to suicide, job loss, and criminal ... become worse over time. Scientists have found that ... this disorder in the short term, including Naltrexone, used to ...
... from Boston University School of Medicine (BUSM) have ... robotic-assisted radical prostatectomy (RARP) is considerably different when ... an open prostatectomy (OP). These findings, which are ... RARP and OP surgery, may have implications for ...
... therapy can completely eradicate some models of cancer, according ... published in the current issue of the British ... from the University of Hull and ETH Zurich ... vessels. When irradiated with light, the molecules create particles ...
... thinking and reasoning abilities of adults who survived childhood ... Survivor Study. Researchers hope the findings will lead to ... population. The work was led by St. Jude Children,s ... to show that childhood cancer survivors are particularly vulnerable ...
... 11, 2011 In a first-of-its-kind study with nuts, ... (ARS) of the United States Department of Agriculture (USDA) ... absorbed by the body. The findings indicate that ... originally thought further validating pistachios as one of ...
... April 10 (HealthDay News) -- An "organic" label on foods ... healthier and tastier, new research suggests. The study included ... were conventionally and organically produced chocolate sandwich cookies, plain yogurt ... but they were labeled as either "regular" or "organic." ...
Cached Medicine News:Health News:In it to win it? 2Health News:Researchers find anatomic differences after robotic-assisted radical prostatectomy 2Health News:Light, chemistry, action -- a new technique to target skin cancers? 2Health News:Fatigue and sleep woes worsen neurocognitive problems in childhood cancer survivors 2Health News:Fatigue and sleep woes worsen neurocognitive problems in childhood cancer survivors 3Health News:Pistachios deliver weight management support, heart health benefits 2Health News:'Organic' Label Seems to Make Food Taste Better 2
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
... and easy-to-use solution that's perfectly suited to ... ,Symeon's light weight and mobility mean that ... working position. It can also be easily ... "spaghetti syndrome" is minimized through the use ...
... 6400 Series anesthesia workstation provides an ... are combined to provide true clinical ... State of the art computer technology ... a single color touchscreen display panel. ...
... used in facilities where space is a ... and gas delivery technologies with an ergonomic ... the functionality of the Draeger Infinity patient ... a workplace environment that is a sound ...
Medicine Products: